申请人:JANSSEN PHARMACEUTICA NV
公开号:US10233173B2
公开(公告)日:2019-03-19
Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.
取代的 1,2,3-三唑作为 NR2B 受体配体。此类化合物可用于 NR2B 受体调节以及治疗由 NR2B 受体活性介导的疾病状态、紊乱和病症的药物组合物和方法中。